Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow–induced pulmonary arterial hypertension in rabbits

Guangqing Cao, PhD, a Chuanzhen Liu, PhD, a Zhaojie Wan, MD, b Kai Liu, PhD, a Hourong Sun, PhD, a Xiangfei Sun, MD, a Mengmeng Tang, MD, a Weidong Bing, MD, a Shuming Wu, PhD, a Xinyan Pang, PhD, a and Xiquan Zhang, PhD a

ABSTRACT

Background: Hyperkinetic pulmonary arterial hypertension (PAH) is a common complication in congenital heart disease, and affects operations, indications, and prognoses for patients. Gene-based stem cell transplantation is an alternative treatment that can attenuate PAH.

Methods: Hyperkinetic PAH rabbit models were successfully established, using common carotid artery and jugular vein anastomosis. Endothelial progenitor cells (EPCs) were isolated from the bone marrow, cultured, and transfected with human hypoxia inducible factor-1 alpha (hHIF-1α), using lentiviruses. Two weeks after the transfected EPCs were transplanted into the rabbits, catheterization was applied to collect hemodynamic data. The hypertrophy of the right ventricle and pulmonary vascular remodeling were evaluated by measuring the right ventricle hypertrophy index, the medial wall thickness, and the medial wall area. Western blot and immunohistochemistry analyses were used to detect the expression of hHIF-1α in the pulmonary small arteries.

Results: Two weeks after transplantation, systolic pulmonary arterial pressure and mean pulmonary arterial pressure were both attenuated. The hypertrophy of the right ventricle, and pulmonary vascular remodeling were reversed. Expression of hHIF-1α in the hHIF-1α–transfected EPCs that had been transplanted was high, and the number of pulmonary small arteries had increased. In addition, combined HIF-1α and homogeneous EPC therapy was more effective at attenuating PAH and increasing the density of pulmonary small arteries, compared with EPC transplantation alone.

Conclusions: Both the therapy with HIF-1α–transfected EPCs, and EPC transplantation, attenuated shunt flow–induced PAH, by means of an angiogenic effect. The former therapeutic method was more effective. (J Thorac Cardiovasc Surg 2015;150:621-32)
Hypoxia inducible factor-1 is a heterodimer consisting of HIF-1 alpha (HIF-1α) and HIF-1 beta (HIF-1β) subunits; its biological activity is determined by HIF-1α. Animal studies show that gene therapy using HIF-1α can promote both angiogenesis and ischemic collateral vessel perfusion, and increase capillary density. These findings indicate that HIF-1 is superior to VEGF, HGF, and other angiogenic growth factors in promoting angiogenesis.

Based on this background, many researchers are looking for more-effective treatments for PAH. As an angiogenic therapeutic strategy, EPC transplantation combined with gene transfer has been used as a novel approach. Compared with EPC transplantation alone, PAH was ameliorated more significantly by transplantation of adenovirus DNA (deoxyribonucleic acid)–modified EPCs in monocrotaline rats. Moreover, treatment with VEGF-transfected EPCs, endothelial nitric oxide synthase–transfected EPCs, and prepro-calcitonin gene–related peptide–expressing EPCs effectively attenuated PAH and reversed pulmonary vascular remodeling. In addition, studies have demonstrated that all of these treatments were more effective than EPC treatment alone.

Therefore, we hypothesized that combined hHIF-1 and homogeneous EPC therapy may be a novel and reliable method to suppress progression of, and reverse, PAH in patients who have congenital heart disease. In this study, we established a hyperkinetic PAH rabbit model, using common carotid artery and jugular vein anastomosis. EPCs were isolated from bone marrow, cultured, and transfected by lentivirus-mediated hHIF-1α in vitro. High hHIF-1α–expressing EPCs were transplanted into the model rabbits to evaluate whether PAH was attenuated and/or pulmonary vascular remodeling reversed.

**METHODS**

**Animal Model Preparation**

One hundred male New Zealand white rabbits (age: 4 weeks; weight: 520 ± 36 g) were provided by the Laboratory Animal Center of Shandong University. The animals received humane care, and the experiments were performed in accordance with the guidelines of the Animal Care and Use Committee of Shandong University. The animals were housed individually at a constant ambient temperature and humidity, and on a 12-hour light–dark cycle.

After 7 days of acclimation, the rabbits were anesthetized with an intravenous injection of pentobarbital sodium (30 mg/kg). A 3-cm incision was made in the middle of the neck, the right external jugular vein was exposed, and 1 mg/kg of heparin was injected intravenously. The right common carotid artery and the right internal jugular vein were carefully dissected. The right common carotid artery was clamped and ligated in the proximal and distal sites, respectively. The right common carotid artery was amputated just before the bifurcation. Under an operative microscope, a 2-mm hole was made in the right internal jugular vein, and an end-to-side anastomosis was made between the right common carotid artery and the right internal jugular vein using a polypropylene (Prolene; Ethicon, Inc, Somerville, NJ) 7-0 suture. Finally, the distal site of the jugular vein was ligated.

Once the artery clamp was released, pulsation and bulging of the proximal part of the jugular vein were observed (Figure 1). Penicillin was locally applied to prevent an infection, and aspirin (10 mg/kg/day) was

---

**Abbreviations and Acronyms**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPC</td>
<td>endothelial progenitor cell</td>
</tr>
<tr>
<td>HGF</td>
<td>hepatocyte growth factor</td>
</tr>
<tr>
<td>HIF-1</td>
<td>hypoxia inducible factor-1</td>
</tr>
<tr>
<td>hHIF-1</td>
<td>human hypoxia inducible factor-1</td>
</tr>
<tr>
<td>PAH</td>
<td>pulmonary arterial hypertension</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
</tr>
</tbody>
</table>

---

Great improvements have been made in the treatment of PAH, such as use of nitrous oxide inhalation, prostacyclin, and other oral drugs. However, the long-term outcome remains unsatisfactory because of the occlusive remodeling of the pulmonary arterioles and the decreased size of the pulmonary vascular bed. Therapeutic angiogenesis has been considered 1 of the most promising recent treatment strategies in fields such as acute myocardial infarction and limb ischemia.

Transplantation of various types of cells has been suggested as a potentially effective angiogenic treatment for PAH. These cell types include bone marrow mesenchymal stem cells, adipose-derived stromal cells, and endothelial progenitor cells (EPCs). This last type is mainly derived from and identified in bone marrow, peripheral blood, and umbilical cord. EPCs have proliferative potential and can differentiate into mature endothelial cells. When PAH occurs, EPCs enter the peripheral blood and migrate to areas of endothelial damage, to replace dysfunctional endothelium. In addition, they can induce angiogenesis and increase the size of the pulmonary vascular bed, which can attenuate PAH.

Transplantation of EPCs can repair endothelial tissues and thus help prevent and treat PAH. However, a single transplantation of cells is not effective in all patients, because of the complicated mechanism of PAH. As a result, gene-based therapy is used as an alternative to treat PAH. In prior studies, we have found that transfection of genes encoding endothelial nitric oxide synthase and hepatocyte growth factor (HGF) can alleviate hyperkinetic PAH in rabbit models. In addition, some studies have indicated that gene transfer of vascular endothelial growth factor (VEGF), prostacyclin synthase, and others ameliorate both angiogenesis and ischemic collateral vessel perfusion, and increase capillary density. These treatments were more effective than EPC treatment alone.
administered as an anticoagulant until the end of the experiment, after the operation. A sham operation was performed by isolating the vessels from rabbits only.

**Isolation and Identification of EPCs**

According to a previously described method, mononuclear cells were isolated from the bone marrow of the long-limb bones of the rabbits using density gradient (Ficoll; Sigma, St Louis, Mo) centrifugation at 2000 g for 30 minutes. Bone-marrow mononuclear cells were washed twice with phosphate-buffered saline and pre-plated onto fibronectin-coated plates with complete EGM-2 medium (Lonza, Walkersville, Md) that included the following: 5% fetal bovine serum, VEGF, fibroblast growth factors–2, epidermal growth factor, insulin growth factor–1, ascorbic acid, hydrocortisone, heparin, and gentamicin/amphotericin-B. After 3 to 4 days of culture at 37°C, with 5% CO2, the nonadherent cells were discarded, and the culture medium was completely changed. All of the cells were further cultured for 2 weeks, and the culture medium was changed every 3 to 4 days.

An evaluation of EPCs was made by examining live cells for their ability to uptake fluorescently labeled acetylated low-density lipoprotein (Dil-ac-LDL, Invitrogen, Carlsbad, Calif). The cells were incubated with the Dil-ac-LDL (10 mg/mL) for 4 hours at 37°C, fixed with 2% paraformaldehyde for 10 minutes, and incubated with 10 mg/mL of fluorescein isothiocyanate–Ulex europaeus agglutinin–1 (Sigma) at 37°C for 1 hour. After unbound dye was washed away, an inverted fluorescent microscope was used to observe the fluorescence.

To characterize the phenotype of the cells, they were detached with trypsin and washed with phosphate-buffered saline containing 0.2% fetal bovine serum. The cells were incubated for 30 minutes with monoclonal antibodies conjugated to fluorescein isothiocyanate or phycoerythrin. Appropriate isotype control combinations were performed. A fluorescence-activated cell sorter (BD FACSCalibur; BD Biosciences, San Jose, Calif) was used to determine CD34, CD133, and VEGF receptor–2 expression. Data acquisition and analysis were performed using BD CellQuest Pro software (BD Biosciences).

**Infection of EPCs with hHIF-1α by Lentiviral Vector**

After approximately 2 weeks in culture, when the EPCs had high proliferation activity, they were infected with a lentivirus carrying 511B–hHIF1α–green fluorescent protein (referred to here as hHIF-EPCs) and CD511B–1–green fluorescent protein (referred to here as control-EPCs; bought from WoRock Bio Tec Co, Shanghai, China), and cultured in a hypoxic incubator. Environmental hypoxic conditions (1%) were achieved in an airtight humidified chamber that was continuously inflated with a gas mixture containing 1% O2, 5% CO2, and 94% N2 at 37°C. A microprocessor-based oxygen controller was used to monitor O2 concentration during incubation (Forma Scientific, Marietta, Ohio). Lentivirus medium was replaced with endothelial cell growth medium–2 after 24 hours. After that, the EPCs were cultured for 72 hours, and the green fluorescent signal emitted by the green fluorescent protein was detected using a fluorescence microscope.

**Experimental Groups**

Animals underwent an echocardiographic examination at 4, 8, and 12 weeks after the operation, to detect the patency of the anastomotic stoma and cardiac function. Catheterization was applied to collect the hemodynamic data after 12 weeks. Animals were anesthetized, followed by exposure of the left jugular vein. A 3F polyethylene catheter was inserted into the vein and advanced first into the right ventricle, and from there into the main pulmonary artery under fluoroscopic guidance. The systemic pressure was monitored by the other catheter inserted into the left common carotid artery. The 2 catheters were both connected to a transducer, and the pulmonary arterial pressure and systemic pressure were recorded. The parameters were recorded 3 times per animal, and the average pressure was calculated. Successful model animals, as well as those with unobstructed anastomosis, were included in the analysis.

After collection of the hemodynamic data, the animal who underwent the sham operation, and those that were successful models, were separated into 6 groups, each with 10 animals: the sham group (underwent the sham operation); the blank group (had no treatment after PAH model was established); the EPCs group (model rabbits who received 10^7 EPCs in 5 mL of endothelial cell growth medium–2 transplanted through the right jugular vein); the hHIF-1-EPCs group (model rabbits who had 10^7 hHIF-1α–transfected EPCs in 5 mL of endothelial cell growth medium–2 transplanted through the right jugular vein); the control-EPCs group (received an injection of 10^7 mock-vehicle–transfected EPCs); and the medium group (injection of 5 mL of only endothelial cell growth medium–2).

**Measurement of Hemodynamic Parameters**

Two weeks after transplantation of the lentivirus-hHIF-1α–infected EPCs, the rabbits were anesthetized with an intravenous injection of pentobarbital sodium (30 mg/kg). Catheterization was applied to collect the hemodynamic data, as previously described. The parameters were recorded 3 times per animal, and the average pressure was calculated.

**Preparation of Heart and Lung Tissues**

Once the hemodynamic data had been collected, the animals were killed with an overdose of pentobarbital sodium. The heart and lungs were rapidly processed and cut into slices before being fixed with 2% paraformaldehyde for 1 hour. After unbound dye was washed away, an inverted fluorescent microscope was used to observe the fluorescence.

**FIGURE 1.** Common carotid artery and internal jugular vein anastomosis: (A) The right common carotid artery and right internal jugular vein were exposed; (B) right common carotid artery and right internal jugular vein anastomosis: (a) right common carotid artery; (b) the right internal jugular vein; (c) anastomosis.
RESULTS
Characteristics of EPCs Derived From Bone Marrow
Bone-marrow mononuclear cells were cultured in endothelial growth medium for 7 days, and exhibited the typical spindle-like shape and polygon that are typical of EPCs (Figure 2, A–C). Endothelial characteristics were assessed by the uptake of Dil-labeled, acetylated–low-density lipoprotein, and the binding of fluorescein isothiocyanate–Ulex europaeus agglutinin–I. Dual-positive adherent cells (Figure 2, D–F) indicated that they expressed the scavenger receptor for acetylated–low-density lipoprotein, and the ligand for Ulex europaeus agglutinin–I. Flow cytometry analysis showed that the cultured bone-marrow mononuclear cells were positive for CD34, CD133, and VEGF receptor–2, as reported previously (Figure 2, G). On the basis of these characteristics, the cells were considered to be bone-marrow EPCs.34,35

Successful Transfection of hHIF-1α Into EPCs
Endothelial progenitor cells were transfected with lentiviral vectors carrying either 511B-hHIF1α-green fluorescent protein or CD511B-1-green fluorescent protein. After infection, 90%-95% of the cultured cells were green fluorescent protein positive (Figure 3, A–D).

Therapy With Combined hHIF-1 and EPCs

ATTENUATED PAH

Hemodynamic analysis and right ventricle hypertrophy index of the 6 groups of rabbits are shown in Figure 4 and Table 1. Compared with the sham group, the systolic pulmonary arterial pressure, the mean pulmonary arterial pressure, and the ratio of the weight of the right ventricle to that of the left ventricle plus septum were significantly increased in the blank and medium groups (P < .05). No significant difference was found between the blank group and the medium group. Compared with the blank group, these 3 measures were significantly lower in the EPC group and hHIF-1-EPC group (P < .05). However, the hHIF-1-EPC group had a more obvious decrease in these 3 variables than the EPC group (P < .05). No significant difference was found between the EPC group and the control-EPC group.

Location of the hHIF-1α–Transfected EPCs and Expression of hHIF-1α in the Lung
No animal died or suffered from other disorders after the cell transplantation. Fluorescent microscopy was used to assess cells labeled with CM-DiL; the red fluorescence continued for several passages (Figure 5, G). The frozen-slice analysis revealed that the engrafted EPCs in the lung were located in the surrounding capillary vessels and alveolar wall, 2 weeks after transplantation, and some EPCs had differentiated and formed a vascular

Statistical Analysis
Data were expressed as mean ± standard deviation (SD). One-way ANOVA with the post hoc Tukey HSD test was used for the statistical analysis among the treatment groups. All of the data in the study were evaluated using SPSS 17.0 (SPSS, Inc, Chicago, Ill).
FIGURE 2. Characteristics and identification of EPCs derived from bone marrow: (A) BM-MNCs cultured for 24 hours were round in shape; (B) BM-MNCs cultured for 7 days were in a typical colony, characterized by cells that are round and spindle-like in shape; (C) BM-MNCs cultured for 14 days were mainly spindle-like and polygonal in shape; (D) Cells with uptake of Dil-acetylated low-density lipoprotein fluoresced red; (E) Cells combined with FITC-Ulex europaeus agglutinin-1 fluoresced green; (F) Dual-positive adherent cells fluoresced in brown-orange; (G) BM-MNCs were positive for CD34, CD133, and vascular endothelial growth factor-2.
structure (Figure 5, A-F). Western blot analysis was used to measure hHIF-1α protein expression; hHIF-1α–specific bands were detected in rabbits in the hHIF-1-EPCs group (Figure 5, H), and no band was observed in rabbits from the other groups.

**Combined hHIF-1α and EPC Therapy Reversed Vascular Remodeling**

To determine the effect on vascular remodeling, we examined the wall thickness and wall area of the small pulmonary arteries and muscular arteries in our rabbits (Figure 6; Table 2). Compared with the sham group, the blank group and the medium group had a significant increase in the wall thickness and wall area of their pulmonary arteries ($P < .05$). No significant difference was found between the blank group and the medium group. The EPC group and the hHIF-1-EPC group had significantly decreased wall thickness and wall area of the pulmonary arteries, compared with the blank group ($P < .05$). However, the wall thickness and wall area decreased more obviously in the HIF-1-EPC group than in the EPC group ($P < .05$). No significant difference was found between the EPC group and the control-EPC group.

**Angiogenic Effect of Combined hHIF-1α and EPC Therapy**

To evaluate the effects of combined hHIF-1α and EPC therapy on endothelial cells, we performed an immunohistochemical examination with antifactor VIII. Compared with the sham group, the blank group and medium group had a significant decrease in capillary density ($P < .05$). A significant difference was found in capillary density between the EPC, hHIF-1-EPCs, and control-EPC groups, compared with the blank group ($P < .05$). However, the hHIF-1-EPC group had a higher capillary density than the EPC group and the control-EPC group ($P < .05$) (Figure 7), indicating that when PAH occurred, pulmonary arterioles were occluded. Transplantation of EPCs increased the number of small arteries, and HIF-1 improved the angiogenic effect.
DISCUSSION
In the research reported in this article, we have established a hyperkinetic PAH model using common carotid artery and jugular vein anastomosis in rabbits, and this model represents the aberrant hemodynamic state in children who have congenital heart disease. In addition, we have successfully transfected the hHIF-1α gene into EPCs, which overexpressed hHIF-1α as a result. After transplantation of hHIF-1α–transfected EPCs into PAH rabbit models, systolic pulmonary arterial pressure, mean pulmonary arterial pressure, and the right ventricle hypertrophy index were significantly decreased. In addition, wall thickness and wall area of the small pulmonary arteries and muscular arteries, which reflect vascular remodeling, were significantly decreased. Compared with EPC treatment alone, these effects were more obvious with the use of combined HIF-1α and EPC therapy. Through immunohistochemical examination of antifactor VIII, we found that microvessel density was greater after transplantation of hHIF-1α–transfected EPCs. This finding indicates that angiogenesis played a key role in the combined HIF-1α and EPC therapy.

Many previous studies have examined the treatment of PAH, including the use of bone marrow cell

![Figure 4](image)

**FIGURE 4.** Hemodynamic analysis and right ventricle hypertrophy index of the 6 groups: (A) systolic pulmonary arterial pressure; (B) mean pulmonary arterial pressure; (C) right ventricle hypertrophy index (RV/LV+S). (Compared with the sham group, *P < .05; compared with the blank group, #P < .05; compared with the EPC group, &P < .05.) The median (horizontal line inside box) is shown as well as a box showing the interquartile ranges (25th and 75th percentile); individual outlier points beyond the 10th and 90th percentiles are indicated. SPAP, Systolic pulmonary arterial pressure; MPAP, mean pulmonary arterial pressure; EPC, endothelial progenitor cell; HIF, hypoxia inducible factor; RV, right ventricle; LV, left ventricle; S, septum.

<table>
<thead>
<tr>
<th>Group</th>
<th>SPAP (mm Hg)</th>
<th>MPAP (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>13.3 ± 1.636</td>
<td>8.97 ± 1.356</td>
</tr>
<tr>
<td>Blank</td>
<td>35.4 ± 2.066*</td>
<td>23.1 ± 1.331*</td>
</tr>
<tr>
<td>EPC</td>
<td>24.5 ± 4.301†</td>
<td>17.3 ± 2.908</td>
</tr>
<tr>
<td>HIF-1-EPC</td>
<td>15.4 ± 1.897‡</td>
<td>10.3 ± 1.515‡</td>
</tr>
<tr>
<td>Control-EPC</td>
<td>26.5 ± 3.136‡</td>
<td>18.0 ± 2.817‡</td>
</tr>
<tr>
<td>Medium</td>
<td>35.9 ± 2.132*</td>
<td>23.4 ± 1.389*</td>
</tr>
</tbody>
</table>

Number in each group is n = 10. F-test: both *P < .05. SPAP, Systolic pulmonary arterial pressure; MPAP, mean pulmonary arterial pressure; EPC, endothelial progenitor cell; HIF, hypoxia inducible factor. Tukey’s test: Compared with the sham group.

*P < .05; compared with the blank group. †P < .05; compared with the EPC group. ‡P < .05.
infusion–attenuated vascular remodeling in a murine PAH model. A novel agonist of the adenosine A2A receptor (LASSBio-1359) provided benefits in the treatment of PAH, and estradiol ameliorated monocrotaline-induced PAH. However, most PAH models have been established using monocrotaline; treatment of the hyperkinetic PAH model, which represents the aberrant hemodynamic state of congenital heart disease, has rarely been reported.

In our study, we tried to build a hyperkinetic PAH model using common carotid artery and jugular vein anastomosis in rabbits. Systolic pulmonary arterial pressure, mean pulmonary arterial pressure, right ventricle hypertrophy index, wall thickness, and wall area of the small pulmonary arteries and muscular arteries were significantly increased in our model system. Our data demonstrated that our hyperkinetic PAH model was successful.

**FIGURE 5.** Location of the hHIF-1α-transfected EPCs, and expression of hHIF-1α in the lung. A, CM-Dil–labeled EPCs formed vascular structure. B, Nuclei of all the cells in the lung slice were stained purple by DAPI (4',6-diamidino-2-phenylindole). C, The vascular structure and nuclei (merged picture of parts A and B). D, hHIF-1α-transfected EPCs formed a vascular structure. E, Nuclei of all the cells in the lung slice were stained purple by DAPI. F, The vascular structure and nuclei (merged picture of parts D and E). G, EPCs labeled with CM-Dil. H, Expression of hHIF-1α in the lung tissues ([a] the hHIF-1α-EPC group; [b] the sham group; [c] the blank group; [d] the EPC group; [e] the control-EPC group; [f] the medium group.). hHIF-1α, Human hypoxia inducible factor-1α; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
The EPCs originate from bone marrow and have the ability to differentiate into multiple cell lines. In ischemic tissues, EPCs have a structural role and differentiate into mature endothelial cells that secrete angiogenic factors. As a result, homogeneous EPC transplantation was used to attenuate ischemic disease, including PAH.\textsuperscript{13,14} In the present study, EPCs in the EPC group were labeled with CM-DiL, and fluorescent microscopy was used to determine the location of the EPCs in the lung. We found that engrafted EPCs in the lung were almost always located in the surrounding capillary vessels and alveolar wall, 2 weeks after transplantation. Finally, compared with the blank group, systolic pulmonary arterial pressure, mean pulmonary arterial pressure, right ventricle hypertrophy index, wall thickness, and wall area of the small pulmonary arteries and muscular arteries decreased significantly in the EPC group. This observation was consistent with previous studies.

In our previous experiments, we discovered that recombinant HGF transfection alleviated hyperkinetic PAH in rabbit models.\textsuperscript{16} HGF is a potent angiogenic gene that promotes angiogenesis and increases capillary density and blood perfusion. This increase in capillary density decreases vascular resistance when blood flow is increased. However, angiogenic growth factors such as VEGF and HGF have potential side effects, including vascular permeability, interstitial edema, and inflammation.

Compared with HGF, HIF-1 has many advantages. First, it increases the size of the vascular bed by signaling the existence of hypoxia, but it has no side effects. Second, HIF-1 is controllable. When PAH occurs, lung tissues are in ischemia and an anoxic state. Overexpression of both HIF-1 and HGF promotes angiogenesis, and PAH is attenuated because of increasing vascular density and blood perfusion. However, when lung tissues are in their normal state, deprived of hypoxia, HIF-1 is not expressed and angiogenesis is blocked.

The observation was consistent with previous studies.

FIGURE 6. Combined therapy with both hHIF-1α and EPCs reduced vascular remodeling: (A) the sham group; (B) the blank group; (C) the EPC group; (D) the hHIF-1-EPC group; (E) the control-EPC group; (F) the medium group.

### TABLE 2. The wall thickness and wall area of the small pulmonary arteries and muscular arteries

<table>
<thead>
<tr>
<th>Group</th>
<th>Small artery (&lt;50 μm)</th>
<th>Muscular artery (51 μm–200 μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>External diameter (μm)</td>
<td>WT (%)</td>
</tr>
<tr>
<td>Sham</td>
<td>35.04 ± 9.14</td>
<td>37.98 ± 5.14</td>
</tr>
<tr>
<td>Blank</td>
<td>32.61 ± 10.17</td>
<td>62.88 ± 6.45</td>
</tr>
<tr>
<td>EPC</td>
<td>33.09 ± 10.76</td>
<td>43.98 ± 2.63</td>
</tr>
<tr>
<td>HIF-1-EPC</td>
<td>34.05 ± 10.29</td>
<td>38.44 ± 3.73</td>
</tr>
<tr>
<td>Control-EPC</td>
<td>35.21 ± 8.28</td>
<td>43.68 ± 2.34</td>
</tr>
<tr>
<td>Medium</td>
<td>33.63 ± 8.29</td>
<td>63.39 ± 5.40</td>
</tr>
</tbody>
</table>

Number in each group is n = 10. F-test: All P < .05. WT, Wall thickness; WA, wall area; EPC, endothelial progenitor cell; HIF, hypoxia inducible factor. Tukey’s test: Compared with the sham group, *P < .05; compared with the blank group, |P| < .05; compared with the EPC group, |P| < .05.
HIF-1 is dehydrated and angiogenesis is terminated. HGF still promotes angiogenesis, and vascular density increases continuously.

Third, HGF is a potent mitogen that has the ability to promote angiogenesis. HIF-1 is a nuclear transcriptional factor that regulates the transcription of downstream genes that mediate cellular and tissue homeostatic responses to altered oxygenation; therefore, HIF-1 gene therapy is more efficient than HGF gene therapy. Some studies have shown that HIF-1 could regulate the expression of its downstream genes, which guide EPC homing and promote neovascularization. In addition, HIF-1-EPC gene transfer could...
augment impaired neovascularization in experimentally induced mouse hind-limb ischemia in vivo. In our study, after the HIF-1-EPC gene was transferred, the hemodynamic changes and vascular remodeling of PAH were attenuated. In addition, the combination of HIF-1 and EPC therapy was more effective than EPC therapy alone.

To explore the mechanism of attenuated PAH in our study, we evaluated capillary density by examining the immunohistochemical expression of antifactor VIII. Compared with the blank group, all of the treatment groups had a significantly higher capillary density. The hHIF-1-EPCs group had a higher capillary density than the EPC group and the control-EPC group. The former demonstrated that transplanted EPCs migrate to the lung tissues and differentiate into mature endothelial cells. HIF-1 regulated and promoted endothelial progenitor cells (EPCs) to migrate to the lung tissues and differentiate into mature endothelial cells. HIF-1 regulated and promoted neovascularization of the EPCs. In addition, we found that the wall thickness and wall area of the small pulmonary arteries and muscular arteries were significantly decreased after treatment.

We speculated that the mechanism of reversing vascular remodeling was associated with the transcription of downstream genes regulated by HIF-1. Some studies have shown that downstream genes related to vascular tone and remodeling include VEGF, α1β-adrenergic receptor, adrenomedullin, endothelin-1, heme oxygenase-1, nitric oxide synthase, matrix metalloproteinase protein, angiotensin-1 receptor, and platelet-derived growth factor-β. The question of whether 1 vascular factor alone, or the interaction of several vascular factors, results in the reversal of vascular remodeling after transplantation of hHIF-1-EPCs deserves further study.

In summary, a hyperkinetic PAH model was successfully established, using the common carotid artery and jugular vein anastomosis technique in rabbits. Transplantation of EPCs attenuated this shunt flow–induced PAH, and transfection of hHIF-1 promoted the effect of EPCs in vivo. The main mechanism of this effect was that angiogenesis gave rise to increasing vascular density and blood perfusion until the normal pulmonary arterial pressure was reached. At present, no effective therapeutic options are available for PAH treatment, despite its poor prognosis. Our study has important implications for hyperkinetic PAH therapy and provides further evidence to support future investigation of regenerative cell-based gene strategies for the treatment of patients who have severe PAH and congenital heart disease.

Conflict of Interest Statement

Authors have nothing to disclose with regard to commercial support.

References


Pulmonary arterial hypertension (PAH) is a progressive disease, characterized by increased resistance in the pulmonary circulation as a result of obstructive remodeling of the pulmonary arterioles. Hyperkinetic PAH represents an old and neovascularization with aging; mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Circulation. 2008;118:754-67.


Key Words: Congenital heart disease, pulmonary arterial hypertension, HIF-1α, endothelial progenitor cells, rabbits